ACC Rockies Chapter Please join our cardiology colleagues at the ACC Annual Meeting, a premier gathering of cardiovascular professionals from around the world. This dynamic conference brings together leading physicians, researchers, healthcare innovators, and industry experts to explore the latest advances in cardiovascular medicine. Attendees will experience cutting-edge clinical education, groundbreaking research presentations, interactive learning sessions, and exceptional networking opportunities focused on improving patient care and advancing the future of heart health.


For more information and to register, please visit: ACC Rockies Chapter Meeting 2026



Alina Robert, MD, FACC Chapter President

Robert Duerr, MD, FACC Incoming Governor

ACC Live Courses
For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings

RSS Latest in Cardiology from ACC.org

  • ATTR-CM: Sex Differences, Delayed Diagnosis and Effect of Acoramidis
    Three recent studies, two published in JACC: Advances and a third published in JAMA Cardiology, investigate sex differences, delayed diagnosis and the effect of acoramidis on heart failure (HF)-related health status in patients with transthyretin amyloid cardiomyopathy (ATTR-CM).
  • ADVANCE OUTCOMES: Ralinepag Reduces Clinical Worsening For PAH
    Ralinepag, a selective prostacyclin IP receptor agonist, significantly reduced the risk of first clinical worsening compared with placebo in patients with pulmonary arterial hypertension (PAH) but was associated with more adverse-event-related treatment discontinuations, according to results of the ADVANCE OUTCOMES trial published July 28 in The Lancet.
  • PARTNER 3: 7-Year TAVR vs. SAVR Outcomes in Low-Risk Patients
    Both TAVR and SAVR were associated with a sustained, substantial improvement in patient-reported health status among patients with severe aortic stenosis (AS) considered at low risk, according to the seven-year outcomes of the PARTNER 3 trial published July 29 in JACC.
  • JACC CKM Guideline Spotlight Issue Addresses Obesity, HF Prevention, More
    The recent release of the 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome marked an important step in defining evidence-based approaches to CKM prevention, risk assessment and treatment.
  • Cardiogenic Shock and Mechanical Circulatory Support: Year in Review 2025
    The year 2025 was a landmark year for cardiogenic shock (CS) and mechanical circulatory support (MCS). Two major clinical guideline documents were published, the longest-duration follow-up data from the field's pivotal trial were released, and real-world registries continued to challenge trial generalizability.